ColoSTAT
Commercial- Indications
- Colorectal cancer
Company intelligence / Profile preview
Rhythm Biosciences develops simple, affordable blood-based diagnostic tests focused on early cancer detection. Its lead product, ColoSTAT®, detects colorectal cancer using five protein biomarkers. The company recently expanded its portfolio by acquiring the Genetype business, adding a suite of genomic and clinical risk assessment tools for various cancers and chronic diseases. Clinical validation studies have shown promising results for both platforms; however, global regulatory approvals are ongoing.
1 more asset in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Rhythm Biosciences.